In a similar trial evaluating sorafenib maintenance in the first six months after allo-HSCT in 202 patients with FLT3-ITD AML, sorafenib conferred improvements in CIR and prolonged LFS and OS (1-year CIR 7.0% vs. 24.5% with placebo, P = 0.001; 2-year LFS 78.9% vs. 56.6%, P < 0.001; and 2-year OS 82.1% vs. 68.0%, P = 0.012) [102]. Here, FLT3 is linked to acute myeloid leukemia.